Journals / Pamukkale Tıp Dergisi / 2019 / Cilt: 12 - Sayı: 3

Visfatin concentration in patients with newly-diagnosed glucose metabolism disorders

Yeni tanı konulmuş glukoz metabolizma bozukluğu olan hastalarda serum visfatin konsatrasyonunun değerlendirilmesi

Pages
401–406
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was statistically significant difference between serum visfatin levels of the groups (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Visfatin, protein secreted by visceral adipose tissue, visfatin is an intracellular enzyme that has insulinmimetic effects and lowers plasma glucose levels.
📊
Key Findings & Data:Materials and Methods: With diagnosis of abnormal glucose metabolism 57 patients were divided into the subgroups according to the oral glucose tolerance test results as impaired fasting glucose (n=39) and impaired fasting glucose+impaired glucose tolerance (n=18).
💡
Conclusion & Impact:There was statistically significant difference between serum visfatin levels of the groups (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Visfatin, protein secreted by visceral adipose tissue, visfatin is an intracellular enzyme that has insulinmimetic effects and lowers plasma glucose levels. Data about the role of visfatin in newly diagnosed glucose metabolism abnormalities are limited. The aim of the work was to assess serum concentration of visfatin in impaired fasting glucose and impaired glucose tolerance. Materials and Methods: With diagnosis of abnormal glucose metabolism 57 patients were divided into the subgroups according to the oral glucose tolerance test results as impaired fasting glucose (n=39) and impaired fasting glucose+impaired glucose tolerance (n=18). The control group consisted of 44 healthy controls with normal glucose tolerance and without any metabolic disorders. Serum lipids, high sensitive C-reactive protein(hsCRP), uric acid, glycated haemoglobin (HbA1c) and serum visfatin levels were measured in all participants. Results: The mean visfatin level of impaired fasting glucose group was 93.92±12.95 ng/mL, impaired fasting glucose+impaired glucose tolerance group was 37.79±29.36 ng/mL and control group was 43.96±38.57 ng/ mL. There was statistically significant difference between serum visfatin levels of the groups (p

Özet

Amaç: Visfatin, visseral adipoz doku tarafından salgılanan, insülinmimetik etkileri olan ve plazma glukoz seviyelerini düşüren hücre içi bir enzimdir. Yeni tanı konulan glukoz metabolizma bozukluklarında visfatinin rolü ile ilgili yapılan çalışmalar sınırlıdır. Bu çalışmanın amacı bozulmuş açlık glukozu ve bozulmuş glukoz toleransı olan hastalarda visfatin serum konsantrasyonunu değerlendirmektir. Gereç ve Yöntem: Anormal glukoz metabolizması tanısı alan 57 hasta, oral glukoz tolerans testi sonuçlarına göre bozulmuş açlık glukozu (BAG) (n=39) ve BAG+ bozulmuş glukoz toleransı (BGT) (n=18) olarak alt gruplara ayrıldı. Kontrol grubu, normal glukoz toleransı olan ve herhangi bir metabolik bozukluğu olmayan 44 sağlıklı bireyden oluşuyordu. Tüm katılımcıların serum lipid, yüksek duyarlı C-reaktif protein(hsCRP), ürik asit, glikozile hemoglobin (HbA1c) ve serum visfatin düzeyleri ölçüldü. Bulgular: BAG grubunun visfatin düzeyi 93,92±12,95 ng/mL, BAG+BGT grubunun 37,79±29,36 ng/mL kontrol grubunun 43,96±38,57 ng/mL idi. Grupların serum visfatin düzeyleri arasında istatistiksel olarak anlamlı fark vardı (p

🔖

Cite This Article

BİLGETEKİN, İ., GÖNDEREN, K., GÖNDEREN, A., YILDIZ, M. (2022). Visfatin concentration in patients with newly-diagnosed glucose metabolism disorders. Pamukkale Tıp Dergisi, Cilt: 12 - Sayı: 3, 401–406. https://ajindex.com/articles/587144

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003
  2. https://doi.org/10.2337/ diacare.26.11.3160 2. Diabetes mellitus çalışma ve eğitim grubu, Türkiye Endokrinoloji ve Metabolizma Derneği, Diabetes mellitus ve komplikasyonlarının tanı, tedavi ve izlem kılavuzu- Güncellenmiş 12. baskı 2019
  3. McGee KC, Harte AL, daSilva NF, et al. Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkb and JNK in Human Abdominal Subcutaneous Adipocytes. PLoS one 2011
  4. 20287. 4. Ognjanovic S, Bao S, Yamamoto SY, Garibay- Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001
  5. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Metab Res Rev 2011
  6. https://doi. org/10.1002/dmrr.1201 6. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985
  7. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004
  8. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006
  9. 2875 https://doi.org/10.2337/db06-0259 9. Brown JE, Onyango DJ, Ramanjaneya M, et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010
  10. https://doi.org/10.1677/JME-09- 0071 10. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006
  11. https://doi. org/10.1210/jc.2005-1475 11. Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006
  12. https://doi.org/10.1042/ CS20050363 12. Stephens JM, Vidal-Puig AJ. An update on visfatin/ pre-B cell colonyenhancing factor, a ubiquitously expressed, illusive cytokine that is regulated in